BioCorteX takes a unique approach to therapeutic delivery by considering three specific interactions between bacteria: the direct effect of drug-bacteria metabolism, the indirect effect of bacteria and the immune system, and the local effects on specific tissues, like the tumour microbiome.
In modern therapeutic development, the makeup of an individual’s microbiome is a complex and expensive problem. The possible microbiome permutations that need to be analysed are almost infinite and performing the necessary analysis takes exceptional computational and financial resources.
As a result, the magnitude of diversity in the human microbiome is overlooked, leading to costly clinical trial failures and the continued use of ineffective legacy medicines to treat life-altering diseases, with varying levels of success.
At BioCorteX our proprietary engines have the ability to conduct advanced computational simulations that model complex human responses, consistently. This can provide the BioCorteX team and partners with the opportunity to test drug-bacteria interactions time and time again, in silico.
By providing actionable insights at the early stage of drug development BioCorteX can de-risk clinical trials, increase chances of trial success and improve internal rates of return, while providing better outcomes for people worldwide.